CORONA Remedies Limited Q1 FY27 results deck summary

Results deck of 31 Jul 2026, summarised by AI from the filing.

Q1 FY27 revenue ₹422.4 cr (+21.9%), EBITDA ₹93.1 cr (+33.5%) and PAT ₹60.1 cr (+30.1%); Hormone Facility at Bhayla inaugurated with EU-GMP certification.

Key takeaways

1. Q1 FY27 revenue Revenue from operations ₹422.4 cr (Q1FY26: ₹346.5 cr, +21.9%).
2. Q1 FY27 EBITDA EBITDA ₹93.1 cr (Q1FY26: ₹69.8 cr, +33.5%); EBITDA margin 22.0% (Q1FY26: 20.1%, +190 bps).
3. Q1 FY27 PAT Profit after tax ₹60.1 cr (Q1FY26: ₹46.2 cr, +30.1%); PAT margin 14.2% (Q1FY26: 13.3%, +90 bps).
4. IPM growth CORONA revenue MAT growth 18.44% vs IPM 8.74%, 1.9x IPM growth, MAT Jun-26.

Original filing on BSE

CORONA Remedies Limited Q1 FY27 results

As filed: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
• Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +2.5% in 28 days (Nifty 500: −4.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

CORONA Remedies Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (3 Aug 2026), Results deck (31 Jul 2026), Results press release (31 Jul 2026)
• Q4 FY26: Earnings call (12 May 2026), Results deck (11 May 2026), Results press release (11 May 2026)
• Q3 FY26: Earnings call (3 Feb 2026), Results deck (2 Feb 2026), Results press release (2 Feb 2026)
• Q2 FY26: Earnings call (5 Jan 2026), Results deck (3 Jan 2026), Results press release (2 Jan 2026)